Cameron Joseph
Verified
As seen in:
POLITICO,
Apple News,
MSN,
MSN Ireland,
MSN UK,
The New York Times,
Business Insider,
Scribd,
The Guardian,
Yahoo Canada,
Yahoo News
and
Politics Editor @politico cjoseph@politico.com
Almanac of American Politics sr. author
Ex-@vicenews @nydailynews @csmonitor
Bylines in @guardian @latimes @cjr
Articles by Cameron Joseph
COPD Treatment Landscape Expands, Yet Significant Gaps in Disease Control and Access Persist, According to Spherix Global Insights
Persistent access barriers leave many treatment candidates without advanced therapy as physicians look for stronger disease control and fewer exacerbations. EXTON, PA – September 8, 2026 – Despite recent treatment advances in chronic obstructive pulmonary disease (COPD), physicians continue to report substantial unmet need, particularly among patients with severe disease and a high risk of exacerbations.
‘Really Alarming for Some Republicans in Competitive Seats’
The midterms are just two months away, and Republicans are growing more nervous. Polls show President Donald Trump is deeply unpopular with voters, and the battle for control of Congress continues to stretch into redder and redder territory. Democrats are feeling confident about their chances of retaking the House even as the GOP successfully redrew more seats to their advantage in the past year's controversial mid-decade redistricting fight..
Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights - Spherix Global Insights
Filspari and Vanrafia lead nephrologists’ most desired pipeline options as physicians seek therapies capable of improving renal outcomes beyond today’s supportive-care paradigm. EXTON, PA, August 31, 2026 – Despite a wave of new therapies reshaping treatment across rare and glomerular kidney diseases, Alport syndrome has largely been left behind. Among kidney diseases evaluated by Spherix Global Insights, nephrologists now rank Alport syndrome as having the greatest unmet need.
As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene Therapy
New Spherix Global Insights research finds mitapivat (Agios) has surged to the top of hematologists’ most desired SCD pipeline therapies, as enthusiasm grows for both oral disease-modifying agents and potentially transformative gene therapies.
Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands
Physicians favor longer trials and therapy augmentation, while tailored combination use signals greater complexity once new options enter the market. EXTON, PA, August 20, 2026 – The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is expanding as prescription therapy becomes integrated into routine patient management.
Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success
Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality. EXTON, PA, August 13, 2026 – The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared.
IL-23 Inhibitors Gain Physician Preference for IBD Across Europe, Yet Actual Use Continues to Lag, According to Spherix Global Insights
New EU4+UK research reveals a sizable gap between growing physician preference for IL-23 inhibitors and their real-world use in Crohn’s disease and ulcerative colitis, highlighting opportunity among undertreated patients. EXTON, PA, August 13, 2026 – The treatment paradigm for inflammatory bowel disease (IBD) may be shifting faster in physician preference than in clinical practice.
New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff
Nephrologists say they would nearly triple Xphozah use without access barriers, but Spherix chart data reveal that physicians substantially overestimate both phosphorus control and combination therapy use among their patients.
Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights
Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as real-world experience grows. EXTON, PA – July 24, 2026 – The U.S. market for PD-1 inhibitors has entered a new phase of evolution.
Sotyktu Begins Defining a New Oral Treatment Segment in Psoriatic Arthritis, According to Spherix Global Insights Launch Research
Early physician experience suggests TYK2 inhibition may expand oral treatment options beyond traditional positioning, with implications for future competitive dynamics in psoriatic arthritis.
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
Medicare’s Maximum Fair Price is being leveraged in commercial rebate negotiations, driving discounts of ~25%–60% and occasionally up to 85% in diabetes categories. Management tools are intensifying across markets, including more prior authorization, step therapy, formulary exclusions, and biosimilar preferencing, with spillover from Part D into commercial benefit design.
Spherix Global Insights Reports Persistent High Unmet Need in Europe’s Evolving MASH Market
Three-quarters of gastroenterologists and hepatologists report high unmet need for MASH therapies, while access to approved treatments remains limited. EXTON, PA, July 8, 2026 — The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease recognition converges with the recent approvals of Madrigal’s Rezdiffra (resmetirom) and Novo Nordisk’s Kayshild (semaglutide).
Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain
Parallel Spherix Global Insights studies reveal expanding biologic use and evolving treatment strategies have yet to fully translate into durable disease control and improved quality of life for many patients.
Novo’s success with oral Wegovy has been fueled by ‘familiarity’: Spherix
Originally published in Fierce Pharma Based on feedback from doctors, Novo Nordisk’s early success with the Wegovy pill may have been fueled in part by familiarity in the market with the GLP-1 compound. (Novo Nordisk) What’s been Novo Nordisk’s secret weapon to turn the tables on Eli Lilly and win the current market battle over their oral GLP-1 obesity drugs? Name recognition.
CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb’s zola-cel, GSK’s Benlysta, and next-generation antifibrotics. EXTON, PA – June 17, 2026 – Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet need, according to findings from the recently updated Special Topix™: ILD in Rheumatology (US) study from Spherix Global Insights.
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time.
Spherix Data Reveals Explosive Demand for Wegovy Pill as $100B Weight Loss Race Intensifies
Tuesday, June 02, 2026 Spherix, the leading independent market intelligence and advisory firm for the global life sciences industry, today announced new research highlighting how the race to dominate the $100 billion weight loss market is accelerating this quarter.
Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies
Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction with current treatment approaches in dermatomyositis and polymyositis.
Eli Lilly’s Oral GLP-1 Foundation Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights
Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill among both primary care physicians (PCPs) and endocrinologists. EXTON, PA, May 27, 2026 — As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients hesitant to initiate injectable weight loss medications.
Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity
On World Hemophilia Day 2026, Spherix Global Insights announces the publication of data revealing early but evolving uptake across novel agents, with growing demand for deeper patient-level insights as treatment pathways diversify EXTON, PA — April 17, 2026 — New data from Spherix Global Insights’ Launch Dynamix™ service indicate that rebalancing agents are continuing to establish a foothold in hemophilia treatment as experience grows, with physician adoption steadily increasing despite...
PK Activation Gains Momentum in Thalassemia Agios’ Aqvesme Launch Reflects Strong Promise with Deliberate Uptake
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake. Exton, PA – March 31, 2026 – Spherix Global Insights today announced new findings from Launch Dynamix™: Aqvesme in Thalassemia, highlighting early physician perceptions and adoption dynamics of Agios’ Aqvesme and its initial integration into clinical practice.
CAR T-cell therapy moving to frontline as myeloma treatment
Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR T-cell therapies will soon became the standard first-line treatment, according to new research from market analytics company Spherix Global Insights. The trend marks a shift in attitudes among myeloma experts. Last year, doctors tended to report more complexity in navigating a rapidly increasing arsenal of myeloma treatments.
CAR-T Moves Upstream in Multiple Myeloma as Physicians Signal Shift in Treatment Sequencing
Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant near-term share gains expected in second-line disease Exton, PA – March 19, 2026 — Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians grow increasingly confident in CAR-T therapy and begin positioning it earlier in the treatment paradigm, despite ongoing uncertainty around...
Saphnelo Surpasses Benlysta in CLE as Physicians Expand Use of Biologics Ahead of Key 2027 Catalysts
Spherix Global Insights finds rising biologic adoption across specialties, with most physicians signaling intent to adopt CLE-specific pipeline therapies earlier in treatment. EXTON, PA — March 17, 2026 – As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted options that may reshape future treatment algorithms.
Disease burden heavy for SCD patients in US, despite promise of gene therapy
New report using real-world data cites care hurdles, need for multiple meds In the U.S., having sickle cell disease (SCD) continues to place a heavy clinical burden on patients, who often require multiple medications, frequent blood transfusions, and the use of opioids to control pain. Most individuals with SCD report high barriers to healthcare, with poor access to treatments and little effective pain management as major issues.
Spherix Global Insights Finds Benlysta Exposure Expanding and Rheumatologists Increasingly Turning to Lupkynis in Lupus Nephritis
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising off-label adoption of SGLT2 inhibitors. EXTON, PA — March 6, 2026 – New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as specialists increasingly incorporate biologics, calcineurin inhibitors, and other targeted therapies into lupus nephritis care.
Paroxysmal Nocturnal Hemoglobinuria Market Enters Transition Phase as Second-Line Opportunities Expand Amid Ongoing Barriers to Adoption of Newer Agents, According to Spherix Global Insights
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and Roche’s PiaSky Exton, PA., March 5, 2026 — Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable population of patients eligible for advanced second-line and later (2L+) therapy – while highlighting persistent clinical practice, referral pathway, and...
Democrats’ divide over Israel erupts after attacks on Iran Original
|
“Palestine has become a litmus test in the party,” said Matt Duss, a former foreign policy adviser to Sen. Bernie Sanders (I-Vt.) and executive vice president at the progressive think tank Center for International Policy. “You see this in both the Michigan and Illinois primaries, where candidates are being pushed to acknowledge that Gaza is a genocide and to pledge not to take AIPAC donations. That was definitely going to continue as we move toward the 2028 presidential primary.
By Adam Wren Verified, Shia Kapos Verified, Elena Schneider Verified, Cameron Joseph Verified, Jessica Piper Verified
|
POLITICO
Verified
Otsuka Pharmaceutical’s VOYXACT Gains Early Traction in IgAN, with 21% of Nephrologists Reporting Prescribing Within Two Months of Approval
Strong clinical advance perceptions and anticipated displacement of other IgAN-targeted therapies position Voyxact for meaningful early momentum, according to the latest findings from Spherix Global Insights. Exton, PA., February 24, 2026 — Two months following the U.S. approval of Voyxact (sibeprenlimab) for IgA nephropathy (IgAN), new data from Spherix Global Insights indicate rapid early uptake and strong physician enthusiasm.
Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies
New Patient Voice Dynamix™ research highlights that even with patients’ high awareness of options and active engagement in their care, systemic barriers and personal limitations from ongoing severe pain keep many patients from experiencing optimal disease control.
Rheumatologists view CAR T-cell therapy as ‘revolutionary,’ but cost, safety temper enthusiasm
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain hesitant on whether its efficacy outweighs the possible risks, according to survey data from Spherix Global Insights. “We are standing at the threshold of major change in rheumatology,” Sawyer May, insights director of rheumatology at Spherix Global Insights, told Healio.
New Spherix Patient Research Shows Nearly Half of Atopic Dermatitis Patients Report Major Quality-of-Life Impact Despite Expanding Treatment Options
Patient-reported data reveal substantial gaps between clinical perception and lived experience across sleep, mental health, and daily functioning EXTON, PA, January 8, 2026 – More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily functioning, according to new research from Spherix Global Insights.
AZ looks to grow reach in lupus with phase 3 win for self-administered Saphnelo
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European approval last month. Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients with a positive phase 3 showing.
Novo's oral semaglutide edges out CagriSema, Lilly's orforglipron as PCPs' most-anticipated obesity med
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before the end of the year. As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers.
UCB’s Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights
High-burden patient segments are driving opportunity for novel pipeline agents, while JAK inhibitors led by AbbVie’s Rinvoq continue to generate strong future interest EXTON, PA, December 17, 2025 — New research from Spherix Global Insights shows that the Hidradenitis Suppurativa treatment landscape is entering a period of accelerated change as dermatologists reassess biologic use based on real-world performance and ongoing unmet need.
Approval of Roche/Genentech’s Gazyvaro Set to Reshape the EU5 Lupus Nephritis Treatment Landscape, According to Spherix Global Insights
Strong physician readiness, high efficacy expectations, and anticipated displacement of off-label rituximab position Gazyvaro for rapid adoption across Europe EXTON, PA, December 11, 2025 — Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights’ latest RealTime Dynamix™: Lupus Nephritis (EU) study indicates that the newly approved biologic is positioned to drive significant therapeutic...
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness. Exton, PA., December 09, 2025 – Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape.
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
Spherix Global Insights’ Latest Market Dynamix™ Report Reveals Intensifying Complexity in Relapsed/Refractory Multiple Myeloma Ahead of ASH 2025 Exton, PA., December 2, 2025 – “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and you’ll get five different answers.
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points. EXTON, Pa., November 19, 2025 – Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the commercial introduction of Gazyva® (obinutuzumab, Genentech/Roche).
Spherix Global Insights Reports Rapidly Evolving U.S. PNH Market as Ultomiris Prescriptions Reach Parity with Iron Supplements
New chart-audit data reveal faster referrals, more patients initiating advanced therapy before hematology consultation, and heightened disease awareness among community physicians.
House to vote as Trump struggles to defuse Epstein issue
The House is expected to pass a bill Tuesday to require the Trump administration to release all files related to convicted sex offender Jeffrey Epstein, a milestone moment for an issue that just won’t go away for President Donald Trump. After fighting the bill’s passage for months, and facing certain defeat, the president threw his support behind it at the last minute on Sunday. “We have nothing to hide, and it’s time to move on,” he declared.
UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth - Spherix Global Insights
New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab.
Novel Pipeline Activity Signals Hope in Systemic Sclerosis, as Rheumatologists Anticipate First Real Therapeutic Advances in Years - Spherix Global Insights
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety and access concerns, according to Spherix Global Insights EXTON, PA, November 6, 2025 – According to the latest Market Dynamix™: Systemic Sclerosis (US) 2025 study from Spherix Global Insights, the treatment landscape for systemic sclerosis (SSc) is poised for meaningful evolution.
Democrats’ election wins caught Trump’s attention. Will shutdown negotiations follow?
Democrats’ sweeping election victories sent a tremor through Washington. The question is whether it is strong enough to knock loose negotiations to end the government shutdown. Blowout wins in Virginia and New Jersey, coupled with comfortable Democratic victories in lower-profile races from swing-states Georgia and Pennsylvania to Maine and California, jolted the White House. For the first time, President Donald Trump admitted the stalemate over the government shutdown is hurting him and his party.
Democrats ride economic anxiety, anti-Trump groundswell to big wins
Democrats have swept the first major elections since President Donald Trump returned to office, a signal that they’re heading into next year’s crucial midterm elections with the wind at their backs as economic concerns drag down the president’s party.
Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix Global Insights.
Trump stalled a New Jersey tunnel - and GOP momentum in this year’s biggest election
Sitting in front of a poster of himself and President Donald Trump in his hometown campaign office, Republican gubernatorial nominee Jack Ciattarelli has nothing but praise for his party’s leader. “His policies have worked, and I support those policies and support him,” Mr. Ciattarelli says. The affable, backslapping, three-time gubernatorial candidate is running not far behind Democratic Rep. Mikie Sherrill in the polls heading into Tuesday’s closely watched election.
Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving immuno-oncology landscape as the next wave of PD-1 biosimilars and subcutaneous (SC) formulations rapidly approach market entry.
Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV) leading prescribing. Exton, PA., October 29, 2025 – Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a comprehensive view of real-world management trends and competitive dynamics within the targeted biologics landscape.
Government shutdown drags on as Republicans, Democrats dig in
Washington is entering the fourth week of a federal government shutdown with no tangible signs it will end anytime soon. Senate Democrats are dug in, insisting that any government funding bill include an extension of expiring tax credits to offset fast-rising health insurance costs. Republicans are still refusing to negotiate while the government remains shut. President Donald Trump and his administration have sought to maximize the sting for Democratic lawmakers.
Show More
loading
Actions
Get in touch with Cameron
Contact Cameron, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack